Course Provider
PESI is a leading continuing education provider for mental health professionals, offering accredited online courses on psychedelic-assisted therapies including MDMA, psilocybin, ketamine, and microdosing, covering clinical frameworks, ethics, harm reduction, and client communication for therapists, counselors, nurses, and psychiatrists. Their trainings help clinicians build competence in this rapidly emerging therapeutic field and earn CE credits required for licensure.
Linked Courses
6
Active Listings
1
Primary Formats
Self-paced, Hybrid
Programs linked directly to this provider in the Blossom course dataset.
By Pesi
In this in-depth online course, gain knowledge from leading experts on how ketamine, MDMA, and psilocybin-assisted therapies can treat complex trauma.
Source lists: 16.3 hours
Delivery: Online + Self-paced
No medicine self-experience listed
By Pesi
“Psychedelic-Assisted Therapy: Breakthrough Treatments for Complex Mental Health Disorders offers clinicians an in-depth training on incorporating psychedelic treatments into their psychotherapeutic practices.
Source lists: 15.5 hours
Delivery: Self-paced + Online
No medicine self-experience listed
By Pesi
Overview of psychedelic therapy research, training standards, neuroscience, global contexts, competencies and best practices for mental health professionals interested in integrating psychedelic-assisted psychotherapy.
Source lists: 1.3 hours
Delivery: Self-paced
No medicine self-experience listed
By Pesi
A 60-minute self-study mini-course on psychedelics and racial justice. It examines how psychedelic research has excluded people of color and considers culturally informed care for ethnic minority communities.
Source lists: 1.1 hours
Delivery: Self-paced
By Pesi
Psychedelics, Hallucinogens, and Entheogens equips mental health practitioners with crucial insights on addressing psychedelic usage in therapeutic settings
Source lists: Estimated 6.3 hours
Delivery: Self-paced
No medicine self-experience listed
By Pesi
This course explores the revived research into psychedelics like MDMA, psilocybin and cannabis for treating PTSD, anxiety, depression and more, including outcomes, therapeutic mechanisms and safe integration with psychotherapy.
Next cohort: Jul 13, 2026
Source lists: 6 hours
Delivery: Online
No medicine self-experience listed